Eisaijevo antiepileptično zdravilo Fycompa injekcijska formulacija je bila predstavljena na Japonskem

TOKIO, 17. april 2024 – (JCN Newswire) – Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. The injection formulation of Fycompa received manufacturing and marketing approval on January 18, 2024 and was included in the Japan’s National Health Insurance (NHI) Drug Price List today.

Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation. Due to concern about the risks of seizures associated with interruption of administration when the drug cannot be taken orally temporarily, such as during surgery, it is suggested that epilepsy patients should continue treatment via routes other than oral administration.

Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and leading to the launch today.

Eisai meni, da je nevrologija, vključno z epilepsijo, terapevtsko področje, ki se osredotoča. Kot podjetje za zdravstveno nego ljudi si Eisai prizadeva zagotoviti "svobodo napadov" večjemu številu bolnikov z epilepsijo. Eisai ostaja zavezan nadaljnji obravnavi raznolikih potreb bolnikov z epilepsijo in njihovim družinam ter povečanju koristi zanje.

Za več informacij obiščite www.eisai.com/news/2024/pdf/enews202426pdf.pdf. 

Poizvedbe v medijih:
Služba za odnose z javnostmi 
Eisai Co., Ltd.
+81-(0)3-3817-5120

• Distribucija vsebine in PR s pomočjo SEO. Okrepite se še danes.
• PlatoData.Network Vertical Generative Ai. Opolnomočite se. Dostopite tukaj.
• PlatoAiStream. Web3 Intelligence. Razširjeno znanje. Dostopite tukaj.
• PlatoESG. Ogljik, CleanTech, Energija, Okolje, sončna energija, Ravnanje z odpadki. Dostopite tukaj.
• PlatoHealth. Obveščanje o biotehnologiji in kliničnih preskušanjih. Dostopite tukaj.
• vir: https://www.jcnnewswire.com/pressrelease/90312/3/